Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 2/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597588 | 0.97 | PLTP (0.46) | PLTPFBP1ALDH1A1TRPV4HPGD | |
| SCHEMBL3606784 | 0.88 | ALDH1A1 (0.49) | FBP1ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL3602639 | 0.83 | HDAC3 (0.36) | GLSCNR1CNR2HDAC3HDAC1 | |
| SCHEMBL3615259 | 0.79 | HDAC3 (0.36) | TSHRGLSCNR1CNR2HDAC3 | |
| SCHEMBL3593422 | 0.79 | XIAP (0.47) | ALDH1A1HPGDTSHRHSD17B10MAPT | |
| Hydrochloric Acid SCHEMBL11260405 | 0.78 | XIAP (0.46) | ALDH1A1HPGDTSHRHSD17B10MAPT | |
| SCHEMBL3606458 | 0.76 | TRPM8 (0.36) | FBP1ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL3609977 | 0.74 | ALDH1A1 (0.64) | ALDH1A1HPGDTSHRHSD17B10MAPT | |
| SCHEMBL3604664 | 0.74 | TRPM8 (0.37) | ALDH1A1HPGDTSHRHSD17B10MAPT | |
| SCHEMBL3596697 | 0.72 | XIAP (0.47) | ALDH1A1HPGDTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | PLTP 4566/4885FBP1 4360/4885ALDH1A1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.